The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from CNW Group

Notice of Cipher Pharmaceuticals Inc. Q4 and Year-End 2012 Conference Call

Thursday, February 21, 2013

Notice of Cipher Pharmaceuticals Inc. Q4 and Year-End 2012 Conference Call09:00 EST Thursday, February 21, 2013Toronto Stock Exchange Symbol: DNDMISSISSAUGA, ON, Feb. 21, 2013 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: DND) (OTC: CPHMF), today announced it will host a conference call for its Q4 and Year-End 2012 financial results on Friday, March 1, 2013.Q4 AND YEAR-END 2012 CONFERENCE CALLWHEN: Friday, March 1, 2013 at 8:30AM ETCONFERENCE CALL/WEBCAST: You can join the call by dialing 647-427-7450 or 1-888-231-8191. A live audio webcast will be available through http://www.cipherpharma.com or http://www.newswire.ca. An archived replay of the webcast will be available for 365 days.About Cipher Pharmaceuticals Inc.Cipher Pharmaceuticals (TSX: DND; OTC: CPHMF) is a growing specialty pharmaceutical company that commercializes novel formulations of successful, currently marketed molecules. Cipher's strategy is to in-license clearly differentiated products, advance them through the clinical development and regulatory approval stages, and out-license to international marketing partners. Cipher's first product is a fenofibrate formulation marketed in the United States as Lipofen®. Cipher's second product, an extended-release tramadol, is marketed in the United States as ConZip® and in Canada as Durela®. Cipher's third product, a novel formulation of the acne treatment isotretinoin, was approved by the FDA in May 2012 and launched in the United States in Q4 2012 as Absorica™. The product was also recently approved by Health Canada and Cipher expects to launch it as Epuris™ in Canada in early Q3 2013.For more information, please visit www.cipherpharma.com.SOURCE: Cipher Pharmaceuticals Inc.For further information: Craig Armitage Investor Relations TMX Equicom (416) 815-0700 ext 278 (416) 815-0080 fax carmitage@tmxequicom.com Larry Andrews President and CEO Cipher Pharmaceuticals (905) 602-5840 ext 324 (905) 602-0628 fax landrews@cipherpharma.com